Today's Date: June 3, 2023
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   UNice Celebrates LGBTQ Pride Month   •   Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting   •   KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i   •   Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl   •   Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   Statement from Minister Hutchings on progress in support of rural Canadians   •   Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
Bookmark and Share

Viatris Inc. (VTRS) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Viatris Inc. Securities Clas

SAN DIEGO , May 26 /Businesswire/ - Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or entities who purchased otherwise acquired Viatris Inc. (NASDAQ: VTRS) common stock between March 1, 2021 and February 25, 2022. Viatris is a global healthcare corporation.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call (800) 350-6003.

What is this Case About: Viatris Inc. (VTRS) Misled Investors Regarding its Business Prospects

According to the complaint, during the class period, Viatris falsely represented that: (i) 2021 was a "trough year" for the Company; (ii) $6.2 billion was the adjusted EBITDA "floor" for Viatris; (iii) its biosimilars business was a core part of the Company’s long-term investment strategy; (iv) it was managing resource allocation to meet its phase one objectives and manage Viatris’ base business erosion; (v) base business erosion was being and would continue to be offset by new product launches, including those in its biosimilars business; and (vi) base business erosion was in line with Defendants’ expectations.

However, Viatris was actually experiencing significantly more competition in its United States complex generics business than disclosed. As a result, the Company was not able to effectively manage its base business erosion or create a stable revenue base. Instead, throughout 2021, Viatris total revenues were declining quarter-over-quarter.

On February 28, 2022, defendants announced Viatris had entered into an agreement to sell its biosimilars business to Biocon Biologics Limited, which was anticipated to close in the second half of 2022. The Company also divulged that it was seeking to divest additional business assets and focus on developing products in three core therapeutic areas as a part of its global reshaping. The same day, Viatris announced lower than expected guidance for fiscal year 2022. On this news, Viatris' stock price declined $3.53 per share, or approximately 24%, to close at $11.01 on February 28, 2022.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Viatris Inc. Shareholders who want to act as lead plaintiff for the class must file their papers by July 14, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Viatris Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.


STORY TAGS: Lawsuit, Class Action Lawsuit, Professional Services, Legal, United States, North America, California,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News